What is claimed is:

1. A pharmaceutical composition comprising a solid dispersion comprising regorafenib and at least one pharmaceutically acceptable excipient inside of the solid dispersion, and at least one stabilizing agent wherein the stabilizing agent is outside of the solid dispersion and the pharmaceutical composition is enteric coated.

2. The composition of claim 1 where in the stabilizing agent is selected from the group consisting of methyl cellulose, ethyl cellulose, hydroxyethyl methyl cellulose (HPMC), hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and its acetate, succinate, proprionate, butyrate, adipate, suberate, sebacate and phthalate ester derivatives like carboxy methyl cellulose, cellulose acetate, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose phthalate acetate succinate, hydroxypropyl methyl cellulose acetate succinate and carmellose sodium and mixtures thereof.

3. The composition of any of claims 1 or 2 wherein the stabilizing agent is selected from the group consisting of hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose acetate succinate (HPMCAS), hydroxypropylmethylcellulose phthalate, hydroxycarboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, croscarmellose sodium and mixtures thereof.

4. The composition of any of claims 1 to 3 wherein the stabilizing agent is selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropyl methyl cellulose (HPMC) or mixtures thereof

5. The composition of any of claims 1 to 4 which is a tablet.

6. The composition of claim 5 is an immediate release tablet.

7. The composition of any of claims 1 to 6 comprising a solid dispersion comprising regorafenib in amorphous form.

8. The composition of any of claims 1 to 7 wherein the solid dispersion comprises a solid dispersion matrix agent selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone/vinylacetate copolymer, polyalkylene glycol, hydroxyalkyl, hydroxyalkyl methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose, polymethacrylates, polyvinyl alcohol, polyvinyl acetate, vinyl alcohol/vinyl acetate copolymer, polyglycolized glycerides, xanthan gum, carrageenan, chitosan, chitin, polydextrin, dextrin, starch, proteins, sucrose, lactose, fructose, maltose, raffinose, sorbitol,

lactitol, mannitol, maltitol, erythritol, inositol, trehalose, isomalt, inulin, maltodextrin, ß-cyclodextrin, hydroxypropyl-ß-cyclodextrin or sulfobutyl ether cyclodextrin or a mixture thereof.

9. The composition of claim 8 wherein the solid dispersion comprises a solid dispersion matrix agent selected from the group consisting of polyvinylpyrrolidone, copovidone, polyethylene glycol, polyethylene oxide or a mixture thereof.

10. The composition of claim 8 or 9 comprising regorafenib and the matrix agent in a weight ratio of 1:0.5 to 1:20.

11. The composition of any of claims 8 to 9 wherein the solid dispersion matrix agent is polyvinylpyrrolidone, croscarmellose sodium and/or microcrystalline cellulose.

12. The composition of any of claims 8 to 9 wherein the pharmaceutically acceptable matrix agent is polyvinylpyrrolidone.

13. The composition of any of claim 12 comprising the regorafenib and the matrix agent in a weight ratio of 1:1 to 1:5.

14. The composition of any of claims 1 to 13 wherein the weight amount of the stabilizing agent in the pharmaceutical composition outside of the solid is at least 2% based on the total weight of regorafenib in the pharmaceutical composition.

15. The composition of claim 14 wherein the weight amount of the stabilizing agent in the pharmaceutical composition outside of the solid is at least 5% based on the total weight of regorafenib in the pharmaceutical composition.

16. The composition of any of claims 1 to 15 wherein the at least one stabilizing agent is present only in the enteric coating.

17. The pharmaceutical composition of any of claims 1 to 16 for use as medicament for treating hyper-proliferative disorders.

18. The pharmaceutical composition of any of claims 1 to 16 for use as medicament wherein the hyper-proliferative disorders are selected from the group consisting of cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases.

19. The pharmaceutical composition of any of claims 1 to 16 for use as medicament wherein the hyper-proliferative disorder is hepatic cell cancer or colorectal cancer.

20. A method of treating hyper-proliferative disorders in a subject in need thereof comprising administering effective amounts of the pharmaceutical composition of any of claims 1 to 16.

21. The method of claim 20 wherein the hyper-proliferative disorder is glioblastoma, colorectal cancer, hepatocellular cancer, lung cancer (e.g. NSCLC) or gastric cancer.

22. A pharmaceutical composition comprising a solid dispersion comprising regorafenib wherein the amount of regorafenib is 30 mg.

23. The method of claim 20 wherein the hyper-proliferative disorder is colorectal cancer or hepatocellular cancer.